CURRICULUM VITAE Jean ENGOHANG-NDONG, Ph.D.
330 University Drive NE New Philadelphia, OH 44663
EDUCATION AND Assistant Professor, Kent State University at Tuscarawas, PROFESSIONAL EXPERIENCE President of International Actions Against Buruli Ulcer (IAABU) Visiting Assistant Professor of Biology, Post-doctoral fellow, Public Health Research Institute, Ph.D., Medical Microbiology, University of Sciences and
My research focuses mainly on fighting infectious diseases in general and
mycobacterial diseases in particular including tuberculosis and Buruli ulcer.
Tuberculosis is caused by Mycobacterium tuberculosis. It is the first and the
most deadly mycobacterial disease. In 2012, about 8.8 million new cases of tuberculosis were diagnosed and 1.5 millions tuberculosis patients died, most of these occurring in developing countries. The increased number of multi-drug resistant and extensively drug resistant tuberculosis cases urges the need to find or develop new anti-tuberculosis drugs. During the past decade, I have worked on unraveling possible mechanisms through which treatment of tuberculosis could be improved using ethionamide, a second-line tuberculosis drug. I have also worked on identifying M. tuberculosis genes that could be used as potential drug targets, including the Iron-dependent Regulator (IdeR) which is essential for M. tuberculosis and involved in acquisition and storage of iron. During the past three years, I have broadened my research interest to Buruli ulcer. Unlike tuberculosis, Buruli ulcer is a neglected disease with about 6000 new cases reported each year from 33 tropical countries. However, it is believed that much more cases occur in endemic areas and that the disease is largely underreported for multiple reasons including cultural believes. Buruli ulcer is a necrotizing and debilitating skin disease that affects with the same chances both males and females. More than 50% of Buruli ulcer patients are children under 15 years old. Buruli ulcer is endemic in Central and Western Africa, in the Americas, in Southeast Asia, and in Western Pacific. However, sub-Saharan African countries record the highest incidence of the disease. Buruli ulcer is caused by Mycobacterium ulcerans, which produces a single toxin called mycolactone and responsible for skin necrosis observed in Buruli ulcer patients.
Molecular mechanisms of Bacterial Pathogenesis The major M. ulcerans genes responsible for mycolactone production (mlsA1, mlsA2 and mlsB) were identified during the past decade. Nevertheless, the complete mechanisms of mycolactone production and its regulation are still unclear. Additionally, the mechanisms through which the toxin is exported from the cell are still to be clarified. In my laboratory, using modern molecular biology, genetic and biochemical techniques, I am interested in understanding these different mechanisms of M. ulcerans pathogenesis. To this date, I am currently studying the level of expression of key mycolactone genes during different stages of M. ulcerans growth. This would allow me to determine if these key mycolactone genes are expressed constitutively or not. In silico analyses I recently performed along with several workbench observations made between last year and now suggest that mycolactone production may be regulated. Thus, I am actively engaged in identifying conditions under which mycolactone production may be affected including the role of population density, iron, temperature and lipids. Drug Discovery Currently, the best treatment for medium size and large size Buruli ulcers consists of a traumatic surgical removal of infected skin tissues followed by skin grafting while small ulcers can be treated with a combination of streptomycin and rifampicin for eight weeks. Nevertheless, in spite of the use of streptomycin and rifampicin for treating small Buruli ulcers, the success of the chemotherapeutic treatment is not always guaranteed. It was recently shown that secondary infections occur often before, during and even after the eight- week treatment with the current chemotherapeutic regimen. Therefore, I am investigating on new Buruli ulcer treatments by testing antimicrobial activities of new anti-tuberculosis drugs on M ulcerans. Jean Engohang-Ndong, Frenois F., Locht C., Villeret V. and 2003
Baulard A.R. 2003. Patent N° 0312801 (PCT/FR2004/002721
CNRS/INSERM/IPL, France) “Ligands of the mycobacterial repressor EthR: selection processes and applications.”
Research/Creative Activity Summer Appointment.
$6,500 (Awarded) Electron beam treatment of sewage sludge.
$52,350 (Awarded by Haley & Aldrich Inc./Arlington County, Research/Creative Activity Summer Appointment.
$6,500 (Awarded) Academic Research Enhancement Award (NIH-R15).
Project title: Mycolactone production: Role of mup045 and
mup038 and regulation of its synthesis.
Post-doctoral grant provided by The New York Community 2004-2006 Trust in the context of The Heiser Program For Research in Leprosy and Tuberculosis. $80,000 (Awarded)
Member of the American Society for Microbiology (ASM) AFFILIATIONS
Member of the Mycobacterium tuberculosis Structural Genomics Consortium
PUBLICATIONS Research papers Jean Engohang-Ndong. Control of microbial population in sludge using electron beam irradiation. (In preparation for submission) Jean Engohang-Ndong and Donald G. Gerbig. 2013. Making basic microbiology laboratory an exciting and engaging experience. Journal of Microbiology and Biology Education. 14(1): 125-126 Jean Engohang-Ndong. 2012. Antimycobacterial drugs currently in phase II clinical trials and preclinical Phase for tuberculosis treatment. Expert Opinion on Investigational Drugs. 21(12):1789-800 Wang S., Jean Engohang-Ndong, Issar Smith. 2007. Structure of the DNA- Binding Domain of the Response Regulator PhoP from Mycobacterium tuberculosis.Biochemistry. 46(51):14751-61 Fréderic Frénois, Jean Engohang-Ndong, Camille Locht, Alain R. Baulard and Vincent Villeret. 2004. Crystal structure of the regulator EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis and leprosy. Molecular Cell. 16(2): 301-307. Jean Engohang-Ndong, David Baillat, Marc Aumercier, Flore Bellefontaine, Gurdyal S. Besra, Camille Locht and Alain R. Baulard. 2004. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, hexamerizes cooperatively on its operator. Molecular Microbiology. 51(1): 175- 188. Alain R. Baulard, Sudagar S. Gurcha, Jean Engohang-Ndong, Kamila Gouffi, Camille Locht, and Gurdyal S. Besra. 2003. In vivo interaction between the polyprenol phosphate mannose synthase Ppm1 and the integral membrane protein Ppm2 from Mycobacterium smegmatis revealed by a bacterial two-hybrid system. Journal of Biological Chemistry. 278(4): 2242-2248. Alain R. Baulard, Joanna C. Betts, Jean Engohang-Ndong, Selwyn Quan, Ruth A. McAdam, Patrick J. Brennan, Camille Locht, and Gurdyal S. Besra. 2000. Activation of the pro-drug ethionamide is regulated in mycobacteria. Journal of Biological Chemistry. 275(36): 28326-28331. Books (Co-author) Jean Engohang-Ndong, S. Allred, D. Cox, and Wendy Ribeiro. 2009. Test bank for Biology Today and Tomorrow, third edition. Belmont CA. Brooks/Cole Cengage Learning.
COMMUNICATIONS Invited speaker
Africa Belle Conference 2012 – Atlanta, Georgia
INTERNATIONAL Fighting Neglected Tropical Diseases in Africa: A Global MEETINGS Approach
The Brown Bag series, Kent State University at Tuscarawas
Tuberculosis Survey in Ohio from 1999 to 2010.
The Brown Bag series, Kent State University at Tuscarawas
IAABU: A partner of choice for fighting Buruli ulcer.
2nd Annual Biological Sciences Day. Université des Sciences May, 2009 et
Mycobacterium ulcerans infection.
1st Annual Biological Sciences Day. Université des Sciences et Jun 08, 2008 Techniques de Masuku, Franceville, GABON. Mycobacterial infections: A challenge for the present and the future.
Honor Program, Brigham Young University Hawaii, Laie HI. Jan 16, 2008 We are all connected by the air we breathe.
More savings with the Join or renew as a Sam’s Plus™ Member and save even more with 10-30% savings on select name-brand and generic prescriptions.** Extra Value Quantity Extra Value Quantity Brand Diabetes Brand Devices and Supplies Generic Diabetes Brand OTC Brand Gastrointestinal Brand Heart Health Generic Heart Health Generic Gastrointestinal * Extra
ß-Glucuronidase Immunotherapy in Dust Mite Allergic Children A Double-Blind Randomized Placebo- Controlled Trial With Short-Term ß-Glucuronidase Therapy in Children With Chronic Rhinoconjunctivitis and/or Asthma Due to Dust Mite E Galli,1 MS Bassi,2 E Mora,3 M Martelli,4 S Gianni,1 G Auricchio,1 1 Research Center San Pietro, Fatebenefratelli Hospital, AfaR, Rome, Italy4Santa